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Abstract
The emergence of regulatory T cells (Tregs) as central mediators of peripheral tolerance in the immune system has led to an
important area of clinical investigation to target these cells for the treatment of autoimmune diseases such as type 1
diabetes. We have demonstrated earlier that in vitro treatment of T cells from healthy individuals with TX527, a low-calcemic
analog of bioactive vitamin D, can promote a CD4+CD25highCD127low regulatory profile and imprint a migratory signature
specific for homing to sites of inflammation. Towards clinical application of vitamin D-induced Tregs in autologous adoptive
immunotherapy for type 1 diabetes, we show here that 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and TX527 similarly imprint
T cells from type 1 diabetes patients with a CD4+CD25highCD127low regulatory profile, modulate surface expression of skin-
and inflammation-homing receptors, and increase expression of CTLA-4 and OX-40. Also, 1,25(OH)2D3 and TX527 treatment
inhibit the production of effector cytokines IFN-c, IL-9, and IL-17. Importantly, 1,25(OH)2D3 and TX527 promote the
induction of IL-10-producing CD4+CD25highCD127low T cells with a stable phenotype and the functional capacity to
suppress proliferation of autologous responder T cells in vitro. These findings warrant additional validation of vitamin D-
induced Tregs in view of future autologous adoptive immunotherapy in type 1 diabetes.
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Introduction
The incidence of type 1 diabetes, in particular in children, is
rising globally and rapidly, making it an important health
challenge worldwide. Current treatment for the acute symptoms,
such as hyperglycemia, is life-long insulin supplementation or
replacement. Nevertheless, long-term complications such as kidney
failure, blindness, heart disease and stroke still occur, emphasizing
the need for novel therapies that can revert or halt disease
progression. So far, none of the immune-based interventions have
been reported to provide long-term disease remission without
affecting normal immunity. Breakdown of the mechanisms that
maintain immune tolerance allow autoreactive T cells to play a
pivotal role in disease pathogenesis [1–3]. The emergence of
regulatory T cells (Tregs) as essential ‘‘masters of immune
regulation’’ [4], because they can potently and selectively
counteract the progressive loss of immune tolerance [5], has led
to the development of Treg-based cellular therapies for the
treatment of autoimmune diseases, transplantation, and graft
versus host disease [5].
In type 1 diabetes, conflicting data are reported on whether
patients have lower [6] or normal [7,8] frequencies of Tregs and
on whether patients have Tregs with defective [9,10] or normal [8]
functional capacity. Yet, targeting the frequency and/or function
of Tregs – whether it is directly in vivo or by ex vivo expansion
followed by autologous adoptive immunotherapy – provides the
advantage of restoring the balance in the immune system without
a generalized immunosuppression. Preclinical studies indeed
support this: for example, adoptive transfer of Tregs expanded
in vitro can prevent and even reverse diabetes in non-obese
diabetic (NOD) mice [11]. In addition, human Tregs can be
isolated from newly-onset type 1 diabetes patients and expanded
in vitro with anti-CD3 and anti-CD28 in the presence of high
doses of recombinant IL-2 [12]. A phase 1 clinical trial currently
tests the safety and efficacy of intravenous infusion into type 1
diabetes patients of autologous polyclonal Tregs expanded in vitro
(NCT01210664). However, the inclusion of additional immuno-
modulatory agents during ex vivo expansion to limit any
inflammatory potential of expanded Tregs may be warranted [13].
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Vitamin D, in particular its active metabolite 1,25(OH)2D3, is
an immunomodulator [14,15] and a wide variety of immune cells
express the nuclear vitamin D receptor (VDR) as well as vitamin
D-activating enzymes [16,17]. Most reports on 1,25(OH)2D3
underscore its actions on antigen presenting cells as the key feature
underlying the immunomodulatory properties [18,19], but acti-
vated T cells also express VDRs [20]. We and others have recently
shown that 1,25(OH)2D3 and the low-calcemic analog TX527 can
directly affect human T cells, inhibiting the production of
proinflammatory cytokines, imprinting a migratory signature
specific for homing to sites of inflammation and promoting a
Treg profile and function [21,22]. Clinical use of such vitamin D-
induced Tregs relies on autologous adoptive immunotherapy and
thus on successful immunomodulation of T cells from type 1
diabetes patients. In this study we found that indeed, exposure to
1,25(OH)2D3 or TX527 inhibits effector cytokine production and
imprints a stable Treg profile on human T cells with suppressive
capacity on autologous T cells, both from control donors and type
1 diabetes patients.
Materials and Methods
Donors and study design
Control individuals were recruited from the general population
at KU Leuven (Leuven, Belgium). Patients with established type 1
diabetes, diagnosed on the basis of clinical criteria [23] and the
presence of autoantibodies, were recruited from the clinical
department of Endocrinology at the University Hospital Leuven.
Duration of diabetes was 14.96.6 years and glycated haemoglobin
A1c (HbA1C) of 8.061.1%. Approximately 30 mL of blood was
collected in EDTA-coated tubes (BD Biosciences, Erembodegem,
Belgium). A sample of serum and cell pellet was stored at 280uC
for biobanking purposes. One part of the peripheral blood
mononuclear cells (PBMCs) was cryopreserved in freezing
medium (50% RPMI, 40% FCS and 10% DMSO) using a cold
freezing protocol. Ethical approval for this study was granted by
the Ethics Committee of the KU Leuven (S52697) and written
informed consent obtained.
mAbs and reagents
T cell medium consisted of RPMI 1640 medium, supplemented
with 10% heat-inactivated FCS, penicillin (100 IU/mL) and
streptomycin (100 IU/mL) (Invitrogen, Ghent, Belgium). Purified
anti-CD3 (UCHT1), anti-CD28 (37407) and human recombinant
IL-1b were from R&D Systems (Minneapolis, USA). Human
recombinant IL-2, human recombinant IL-6, and human recom-
binant TGF-b were from PeproTech (Rocky Hill, USA). TX527
[19-nor-14,20-bisepi-23-yne-1,25(OH)2D3], a 1,25(OH)2D3-ana-
log, was synthesized by M. Vandewalle and P. De Clercq
(University of Ghent, Ghent, Belgium) and obtained from
The´ramex S.A. (Monaco, France). 1,25(OH)2D3 (calcitriol) was
from Sigma-Aldrich (St. Louis, USA).
T cell isolation and culture
PBMCs were isolated by Percoll-gradient centrifugation (Axis-
Shield Pc AS, Oslo, Norway) from fresh whole blood samples.
CD3+ T cells were purified from PBMCs by negative selection
using the Pan T cell Isolation Kit II (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to manufacturer’s protocol (purity
always.96%). Purified CD3+ T cells (16106 cells/mL) were
cultured in 24-well culture plates in T cell medium with plate-
bound anti-CD3 and anti-CD28 (both 1 mg/mL). Every other day,
cells were split and supplemented with fresh T cell medium
containing human rIL-2 (125 U/mL) and treated with
1,25(OH)2D3, TX527 (10
28 M) or vehicle (ethanol) starting at
day 2. This treatment schedule is chosen based on previous results
showing an optimal induction of VDR expression on day 2
following activation [22,24]. To evaluate the stability of the
induced Treg population, cells were stimulated with a cytokine
cocktail containing 50 ng/ml rIL-1b, 125 U/ml rIL-2, 50 ng/ml
rIL-6 and 3 ng/ml TGF-b during the last 48 h of the T cell culture
as previously described [25,26].
Analysis of cell populations and isolation for functional
studies
Tregs in PBMCs at baseline were quantified using flow
cytometry after staining with anti-CD4-APC, anti-CD8-eFluor780
(eBioscience, San Diego, CA), anti-CD25-PE (Miltenyi) and anti-
CD127-PECy7 (BD Biosciences). Staining for surface protein was
done with anti-CD4-Pacific Orange (Life Technologies), anti-
CD8-APC-eFluor780 (eBioscience), anti-CD45RO-PerCP-
eFluor710 (eBioscience), anti-OX40-FITC (BD Biosciences),
anti-CCR10-PE (R&DSystems), anti-CXCR6-AF647 (BioLe-
gend), and anti-CLA-Pacific Blue (Life Technologies) (30 min,
37uC). For FOXP3/CTLA-4 intracellular staining, cells were
incubated with anti-CD4-Pacific Orange, anti-CD8-APC-
eFluor780, anti-CD25-PE, anti-CD127-PECy7, and anti-
CTLA4-APC (BD Biosciences)(20 min, 4uC), then fixed and
permeabilized using the human FOXP3 Buffer Set (BD Biosci-
ences), according to manufacturer’s instructions, and incubated
with anti-FOXP3-AF488 (eBioscience) and anti-CTLA4-APC
(30 min, RT). Samples were acquired on a Gallios flow cytometer
(Beckman Coulter) and analyzed with FlowJo (TreeStar, Ashland,
USA). For RNA preparation or functional studies,
CD4+CD25highCD127low cells were sort-purified from cultures
using a FACSAriaTM I cell sorter (BD Biosciences). Moreover, for
the functional studies, CD4+ T cells were magnetically isolated
from T cell cultures using the human CD4+ T cell isolation kit
(Miltenyi) according to the manufacturer’s guidelines.
RNA isolation and real-time RT-PCR
RNA was extracted from sorted CD4+CD25hiCD127low using
the RNeasy Micro-kit (Qiagen, Venlo, The Netherlands). Con-
centration and purity of extracted RNA was determined using the
NanoDrop spectrophotometer. RNA samples (1 mg or less) were
reverse transcribed by preincubating with 5 mM oligo(dT)16 (Life
Technologies; 10 min, 70uC), then incubation with 5x First Strand
buffer, 0.1 M DTT, 10 mM dNTP and 100 U Superscript II
Reverse Transcriptase (Invitrogen)(80 min, 42uC). RT-PCR reac-
tions were as previously reported [22,24] using StepOnePlus Real-
Time PCR System and SYBR Green or Taqman systems (Applied
Biosystems, Foster City, CA). Primer and probe sets were reported
earlier [22,24] and used at 400 nM and 200 nM respectively.
RPL27 and B2M were used as normalization genes. The DDCt
method was used for data analysis.
In vitro suppression assay
Stored autologous PBMCs were labeled with 1 mM CFSE
(Biochimika), used as responders and stimulated with soluble anti-
CD3 and anti-CD28 (1 mg/mL). Unsorted CD4+ and sort-purified
CD4+CD25highCD127low T cells were added at indicated ratios.
After 72 h, cells were stained anti-CD4-PacOrange, anti-CD8-
PECy7, anti-CD44-eFluor450 (eBioscience), Fixable Viability Dye
eFluor780 (eBioscience). Responder proliferation was determined
using CFSE dilution. The percentage of suppression was
calculated as: 1006(1– [(% CFSEdim) in the presence of Tregs]
Vitamin D3 for Treg in Type 1 Diabetes
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divided by [(% CFSEdim) in the absence of Tregs], where CFSEdim
reflects cells that underwent.1 division.
Cytokine measurement
For the quantitative detection of cytokines in the supernatant,
the Human Th1/Th2/Th9/Th17/Th22 13plex Kit FlowCyto-
mix (eBioscience) was used according to manufacturer’s recom-
mendations. Samples were measured using the Gallios flow
cytometer (Beckman Coulter) and analyzed with the FlowCyto-
mixPro Software (eBioscience).
Statistics
The normality of all datasets was tested using D’Agostino-
Pearson omnibus normality test. Where data did not significantly
deviate from the normal distribution, either an independent or
paired Student t test was used to test for significance as indicated.
Where data were found to significantly deviate from the normal
distribution, statistical significance was determined using Mann-
Whitney test (unpaired data). All statistical analyses were
performed using Prism (GraphPad Software, La Jolla, CA).
Significance was defined as ns: not significant; *P,0.05; **P,
0.01; ***P,0.001.
Results
Similar vitamin D status and Treg frequency in donor
cohorts
Lower concentrations of serum 25(OH)D3, considered to be the
best estimate of body stores of vitamin D [27], have been detected
in children or young adults with newly-diagnosed type 1 diabetes
in comparison to control subjects [17]. In this study, we found
comparable serum concentrations of 25(OH)D3 in control donors
and patients (Fig. S1B). Stratification of serum 25(OH)D3
concentrations per season revealed an expected seasonal pattern
with the highest concentrations in the summer months and lowest
concentrations in the spring/winter, in line with the amount of
available ultraviolet (UV) B irradiation in the preceding months
(Fig. S1B). Of note, the same blood samples were used to
determine serum 25(OH)D3 concentrations as well as for immune
analysis (see below).
Exposure to 1,25(OH)2D3 or TX527 reduces production of
helper T cell cytokines
We have previously shown that TX527, a low-calcemic analog
of 1,25(OH)2D3, modulates the cytokine expression profiles of
human T cells [22]. To determine how 1,25(OH)2D3 and TX527
affect the differentiation of T cells from type 1 diabetes patients,
we measured the cytokine production by CD3+ T cells after
culture in the presence of 1,25(OH)2D3 and TX527. For this
purpose, human CD3+ T cells were isolated from PBMCs of
control subjects and patients with type 1 diabetes, activated using
anti-CD3 and anti-CD28 and cultured as described in the
Research Design and Methods section. Cells were treated with
vehicle (ethanol), 1028 M 1,25(OH)2D3 or 10
28 M TX527 every
other day. On 8 day, cytokine concentrations were determined in
the culture supernatant using a multiplex detection system.
We found a higher concentration of IFN-c, TNF-a, and IL-17A
in vehicle-treated T cell cultures from donors with type 1 diabetes
than in those from control donors, suggesting more cytotoxic T
cells, Th1 and Th17 cells, in line with the inflammation associated
with type 1 diabetes (Fig. 1). Exposure of T cells to either
1,25(OH)2D3 or TX527 reduced the production of Th1 cytokines,
as demonstrated by the decrease in produced IFN-c and TNF-a
(Fig. 1). This was evident in cultures from both type 1 diabetes and
control donors. Both 1,25(OH)2D3 and TX527 also reduced the
Th2 cytokines IL-13 (Fig. 1) and IL-4 and IL-5 (data not shown) in
cultures from control and type 1 diabetes donor T cells, albeit not
always statistically significant. Moreover, production of Th9 (IL-9)
and Th17 (IL-17A) cytokines by T cells from control subjects and
type 1 diabetes donors were reduced after exposure to
1,25(OH)2D3 or TX527 (Fig. 1). IL-22 and IL-12 were hardly
detected using this approach (data not shown). Taken together,
these data show that both the natural bioactive vitamin D
compound 1,25(OH)2D3 and the low-calcemic analog TX527
reduce the cytokine production irrespective of whether the T cells
were isolated from type 1 diabetes patients or control donors.
1,25(OH)2D3 and TX527 induce receptors responsible for
homing to skin and inflammation
To gain insight into the role of 1,25(OH)2D3 and TX527 as
potential modulators of T cell movement, we analyzed the surface
expression of the skin-homing receptors C-C chemokine receptor
type 10 (CCR10) and cutaneous leukocyte-associated antigen
(CLA), and the inflammation-associated homing receptor C-X-C
chemokine receptor type 6 (CXCR6). We and others had
previously published that 1,25(OH)2D3 or TX527 increases the
expression of CCR10 in T cells from control subjects [22,28]. On
day 8, both 1,25(OH)2D3 and TX527 had induced CCR10 on
CD4+ and CD8+ T cells, not only from control donors, but also
from patients with type 1 diabetes (Fig. 2). On the other hand,
exposure to 1,25(OH)2D3 or TX527 decreased the expression of
CLA on CD4+ and CD8+ T cells from both control subjects and
type 1 diabetes patients. In addition, 1,25(OH)2D3 or TX527
triggered elevated expression of CXCR6, a chemokine receptor
guiding T cells to sites of inflammation, on CD4+ T cells, but did
not influence CXCR6 expression on CD8+ T cells. Overall, these
data suggest that 1,25(OH)2D3 or TX527 alters the migratory
behavior of human T cells towards chemokine ligands by
modulating their homing receptor expression profile. This may
assist proper homing of conditioned T cells upon adoptive transfer
in vivo.
Exposure to 1,25(OH)2D3 or TX527 promotes a Treg
phenotype
We found a similar CD4-to-CD8 ratio and a similar frequency
of CD4+CD25highCD127low T cells in PBMCs freshly isolated
from control subjects or from patients with type 1 diabetes (Fig.
S2). It is important with regards to therapeutic application of ex
vivo-expanded autologous Treg to investigate whether triggering
the VDR pathway also increases Tregs in T cells from patients
with type 1 diabetes, similar to what we had shown in human
CD3+ T cells from control subjects [22].
A first indication that VDR agonists such as 1,25(OH)2D3 also
induce a Treg phenotype in T cells from type 1 diabetes patients
came from our data on CD134 (OX-40), a secondary co-
stimulatory molecule that is constitutively expressed in naturally
occurring CD4+ Tregs (nTregs) in mice and upregulated on the
surface of human nTregs upon TCR cross-linking [29]. We found
increased frequencies of OX-40-expressing CD4+ T cells after
exposure of T cells from patients with type 1 diabetes to
1,25(OH)2D3 or TX527 (Fig. 3A), suggesting increased presence
of Tregs. Indeed, assessment of surface expression of CD25 and
CD127 on CD4+ T cells by flow cytometry showed that
1,25(OH)2D3 and TX527 increased the frequency of
CD4+CD25highCD127low T cells in cultures of human T cells
from patients with type 1 diabetes (Fig. 3B). In addition,
Vitamin D3 for Treg in Type 1 Diabetes
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1,25(OH)2D3 and TX527 were equally powerful at inducing this
effect. We then analyzed the expression of molecules involved in
Treg development and function. Within the CD4+CD25highC-
D127low T cell population, 1,25(OH)2D3 or TX527 increased the
expression of the Treg-associated molecule cytotoxic T lympho-
cyte antigen 4 (CTLA-4, CD152) in T cells of control subjects and
patients with type 1 diabetes (Fig. 3C). Somewhat surprisingly,
FOXP3, a transcription factor that plays a key role in Treg
development and function [30], was reduced after exposure to
1,25(OH)2D3 or TX527 in the CD4
+CD25highCD127low T cell
population, both in frequency of FOXP3+ cells (Fig. 3D) and the
FOXP3 expression levels (data not shown). It is important to
emphasize that these ‘vitamin D effects’ were observed in T cells
from each individual donor, a phenomenon that remains
underrepresented in the box plots shown. Taken together, these
observations led to the conclusion that in vitro, VDR agonists can
promote expansion of CD4+CD25highCD127low Tregs in control
subjects and patients with type 1 diabetes. One of the major
concerns for Treg therapy is that they may change their phenotype
upon encountering an inflammatory environment. To address this
issue, end-stage 1,25(OH)2D3- or TX527-treated cultures were
exposed to a cocktail of proinflammatory cytokines known to
promote effector T cell reactivity [25,26]. Strikingly we showed a
similar upward trend in the frequency of OX-40-expressing
1,25(OH)2D3- or TX527-treated CD4
+ T cells from patients with
type 1 diabetes (Fig. 3E) even after additional stimulation with
such a robust cytokine cocktail. Supporting this finding, elevated
numbers of CD4+CD25highCD127low T cells in cultures of
1,25(OH)2D3- or TX527-treated T cells from patients with type
1 diabetes were detected, thereby confirming the increased
Figure 1. 1,25(OH)2D3 and TX527 reduce T helper cytokines in human T cell cultures. Human peripheral blood CD3
+ T cells, isolated from
control subjects (n = 19) and type 1 diabetes patients (n = 20), were activated using anti-CD3/CD28 and treated with vehicle (CTR), 1028 M
1,25(OH)2D3 (1,25D3) or 10
28 M TX527. Concentrations of indicated cytokines were determined in the supernatant of day 8 cultures. Results are
shown as bar graphs of mean 6 SEM, data are grouped per treatment and donor type. Significance was calculated using a two-tailed Mann-Whitney
test. * P,0.05; ** P,0.01; *** P,0.001. All other comparisons were not statistically significant.
doi:10.1371/journal.pone.0109194.g001
Figure 2. Induction of CCR10 and CXCR6 and reduction of CLA on activated T cells. Expression of CCR10, CLA or CXCR6 by CD4+ (A) and
CD8+ T cells (B) after activation of T cells from control subjects (Control, n = 33) or type 1 diabetes patients (T1D, n = 45) in the presence of vehicle
(CTR), 1028 M 1,25(OH)2D3 (1,25D3) or 10
28 M TX527. On day 8, cells were harvested and stained for flow cytometry. Shown are box and Tukey
whisker plot summarizing the frequencies of positive cells in the CD4 or CD8 gate respectively, data are grouped per donor type and treatment,
cross-bar indicates median. Significance was calculated using a two-tailed Mann-Whitney test. * P,0.05; ** P,0.01; *** P,0.001. All other
comparisons were not statistically significant.
doi:10.1371/journal.pone.0109194.g002
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presence of Tregs after cytokine exposure (Fig. 3F). Finally, also
markers involved in Treg function such as CTLA-4 (Fig. 3G) and
FOXP3 (Fig. 3H) were similarly regulated by 1,25(OH)2D3 or
TX527 in T cells from patients with type 1 diabetes after
additional proinflammatory cytokine stimulation. Combined,
these data support a stable regulation of the promoted Treg
phenotype by 1,25(OH)2D3 as well as TX527.
1,25(OH)2D3 and TX527 decrease IFN-c, IL-4 and IL-17
and increase IL-10 in sorted Tregs
To examine whether administration of 1,25(OH)2D3 or TX527
directly influenced T cells, we analyzed the expression of VDR
and vitamin D-related genes directly in Treg populations. For this
purpose, CD3+ T cells were cultured as described above and
CD4+CD25highCD127low T cells were sorted at the end of the
culture. We found that treatment with 1,25(OH)2D3 or TX527
strongly induced the direct vitamin D-target gene 24-hydroxylase
(24-OHase, known as CYP24A1) and slightly increased expression
of VDR (data not shown), demonstrating a direct regulation by
ligand (1,25(OH)2D3 or TX527)-bound VDR in the
CD4+CD25highCD127low T cells.
In addition, we analyzed the effects of 1,25(OH)2D3 or TX527
on the T cell cytokine profile of human CD4+CD25highCD127low
T cells. In line with the cytokine production in the supernatant of
bulk T cell cultures (Fig. 1), exposure to 1,25(OH)2D3 and TX527
almost completely abrogated the Th1, Th2 and Th17 cytokine
function of CD4+CD25highCD127low T cells, as demonstrated by
the near basal levels of IFN- c, IL-4 and IL-17A mRNA,
respectively (Fig. 4). Importantly, 1,25(OH)2D3 and TX527 did
not inhibit T cell cytokine production across the board, because a
specific upregulation of the immunoregulatory cytokine IL-10 was
observed within the CD4+CD25highCD127low T cell subset
(Fig. 4), whereas expression of IL-2 and TGF- b remained
unchanged (data not shown). This suggested that the Tr1 cytokine
activity is increased in the expanded Treg populations, both from
control donors and from patients with type 1 diabetes. Taken
together, 1,25(OH)2D3 and TX527 affected transcription of
previously described immune-related vitamin D targets, indicating
immunomodulatory actions on CD4+CD25highCD127low T cells
independent of antigen presenting cells.
Unsorted CD4+ and sorted CD4+CD25highCD127low T cells
retain suppressive capacity after culture with
1,25(OH)2D3 or TX527
We next tested whether 1,25(OH)2D3- or TX527-induced
Tregs exhibit functional capacity to suppress autologous T cell
responses. When adding the unsorted CD4+ T cells from vehicle-,
1,25(OH)2D3-, or TX527-treated cultures to CFSE-labeled
autologous PBMC responder cells in a standard suppression assay,
a higher suppression of both CD4+ and CD8+ T cell populations
was seen than with vehicle-treated cells, with similar effects in
immune cells from control subjects or patients with type 1 diabetes
(Fig. 5A). However, when sorted CD4+CD25highCD127low T cells
from vehicle-, 1,25(OH)2D3-, or TX527-treated cultures were
added to the in vitro suppressor assay, this difference was
diminished (Figure 5B), suggesting that 1,25(OH)2D3- or
TX527-induced Tregs were not more potent on a cell-by-cell
basis, but more frequent in numbers. This is in line with our
observation that more CD4+CD25highCD127low T cells were
recovered from 1,25(OH)2D3- or TX527-treated cultures than
from untreated cultures (data not shown). However, the effect of
1,25(OH)2D3 or TX527 on Treg induction was identical for
control subjects and patients with type 1 diabetes.
Discussion
In recent years, interest in the tolerance-inducing potential of
vitamin D and its analogs to modulate immune cells has grown,
but one of the major obstacles for the use of active vitamin D is the
need for supra-physiological doses to modulate immune responses,
because of side-effects such as hypercalcemia, hypercalciuria and
kidney stones. The use of structural analogs of 1,25(OH)2D3 with
reduced calcemic effects but similar immunoregulatory activity
might overcome this issue, but no clinical (safety) data are
available. Therefore, we opted to ex vivo manipulate T cells with
1,25(OH)2D3 for subsequent use in autologous adoptive immuno-
therapy. We recently demonstrated that ex vivo treatment of
human T cells from healthy individuals with TX527, a vitamin D
analog with reduced calcemic side effects, triggers the emergence
of a CD4+CD25highCD127low T cell population [22]. To further
explore the clinical applicability of 1,25(OH)2D3 and TX527 in
the context of autologous adoptive T cell therapy, we show here
that 1,25(OH)2D3 or TX527 can also imprint T cells from type 1
diabetes patients with a stable regulatory profile (even in the
presence of a severe systemic inflammatory response) and a
suppressive capacity on autologous T cells. These results are
particularly relevant to the use of Tregs as an adoptive cell
therapy.
Many immunotherapies have failed to dampen the autoimmune
process in type 1 diabetes without simultaneously affecting normal
immunity. The emergence of Tregs as central mediators of
peripheral tolerance in the immune system has led to an important
area of clinical investigation to target these cells for the treatment
of autoimmune diseases such as type 1 diabetes. Deficits in the
number and/or suppressive activity of Tregs, which have been
implicated in sustaining immune homeostasis, have been postu-
lated as underlying mechanisms by which individuals develop type
1 diabetes. However, to date, there is controversy about whether
Treg frequency and/or function are impaired at type 1 diabetes
onset [6–10,31,32]. In line with previous findings [7,8], we have
confirmed normal CD4+/CD8+ T cell ratios and the Treg
frequencies in our type 1 diabetes patient cohort. Increasing the
frequency and/or function of Tregs has been proposed as a
potential therapy in type 1 diabetes and can be achieved by either
targeting these cells directly in vivo or by expanding them ex vivo
prior to re-introduction in the patient. Currently, a phase 1 clinical
trial of CD4+CD25+CD127low/- polyclonal Tregs expanded using
anti-CD3 and anti-CD28 coated microbeads and IL-2 is ongoing
(NCT01210664). While we did not directly compare the Treg
expansion protocol used with our approach, we believe that
addition of active vitamin D (analog) might benefit ex vivo
expansion protocols because it imprints the cells with a migratory
signature towards sites of inflammation [22], reduces pro-
inflammatory cytokine production and induces anti-inflammatory
IL10. More specifically, our results showed a similar 1,25(OH)2D3-
and TX527-mediated modulation of CCR10 and CLA expres-
sion, in line with a previous report showing that CCR10
expression increased on human CD4+ and CD8+ T cells upon
activation in the presence of 1,25(OH)2D3 [22,24,28,33]. It is also
important in the context of type 1 diabetes, which is associated
with IFN-c producing Th1 cells, IL-17A producing Th17 cells and
an increase in IL-9+IL-17+ cells, that exposure of T cells from type
1 diabetes donors to 1,25(OH)2D3 and TX527 reduced produc-
tion of all tested helper T cell cytokines. This inhibitory effect on
Th1 (IFN-c) and Th17 (IL-17) production is also consistent with a
variety of other studies regarding the direct effect of VDR agonist
on mouse and human T cells [21,22,24,34–36]. For example,
stimulation of CD4+CD25- human T cells with anti-CD3/CD28
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Figure 3. 1,25(OH)2D3 and TX527 trigger a stable Treg phenotype in T cells from human type 1 diabetic patients. T cells from control
subjects (Control) or type 1 diabetes patients (T1D) were cultured in the presence of vehicle (CTR; white boxes), 1028 M 1,25(OH)2D3 (1,25D3, grey boxes)
or 1028 M TX527 (black boxes). On day 6, the T cell cultures were exposed to normal T cell medium (left panel:A-D) or a cytokine cocktail (right panel: E-
H) as described in the methods section. T cells were harvested 48 h later and stained for flow cytometry. Box and Tukey wisker plot summarizes the
frequencies of positive cells in the CD4+ T cell gate. A: Surface expression of OX-40 (CD134) by activated CD4+ T cells of control donors (Control, n = 43)
or type 1 diabetes patients (T1D, n=58). B: Frequency of CD25highCD127low cells in the CD4+ T cell gate from control subjects (Control, n = 4) and type 1
diabetes patients (T1D, n= 7). CTLA-4 (C) and FOXP3 (D) expression in CD4+CD25highCD127low T cells of control donors (Control, n = 28) and type 1
diabetes patients (T1D, n= 45). E: Frequency of OX-40 expression on CD4+ T cells from control subjects (Control, n = ) or type 1 diabetes patients (T1D,
n= 7) after additional stimulation with a cytokine cocktail. F: Frequency of CD25highCD127low cells in CD4+ T cells. CTLA-4 (G) and FOXP3 (H) expression
in the CD4+ CD25highCD127low T cell gate. Data are grouped per donor type and treatment, cross-bars indicate median 6 SEM. Significance was
calculated using a two-tailed Mann-Whitney test. * P,0.05; ** P,0.01; *** P,0.001. All other comparisons were not significantly different.
doi:10.1371/journal.pone.0109194.g003
Vitamin D3 for Treg in Type 1 Diabetes
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e109194
beads in the presence of 1,25(OH)2D3 inhibited the production of
inflammatory cytokines, such as IFN-c, IL-17 and IL-21 [21].
Exposure of human T cells to 1,25(OH)2D3 and TX527 increased
IL-10 mRNA in sorted CD4+CD25highCD127low T cells, in line
published data on increased IL-10 production after in vitro
exposure of mouse and human T cells to VDR agonists [21,22,37].
Intriguingly, the vitamin D-induced Tregs exhibited the
capacity to suppress proliferation of autologous responder T cells.
Because it is clinically only relevant to know whether Tregs from
T1D patients can suppress autologous effector T cell responses, we
did not evaluate whether Tregs generated from T1D patients are
relatively more or less potent than those from control donors using
cross-over experiments. Instead we showed elevated levels of
Figure 4. 1,25(OH)2D3 and TX527 reduce IFN-c, IL-4, and IL-17 but increase IL-10 in expanded human CD4
+CD25highCD127low T
cells. Peripheral blood CD3+ T cells from control donors (n = 5) or type 1 diabetes patients (n = ) were cultured for 8 days in the presence of 10-8 M
1,25(OH)2D3 (1,25D3) or TX527 or corresponding concentration of vehicle (CTR). CD4
+CD25highCD127low T cells were sort-purified and mRNA
expression of IFN-c, IL-4, IL-17, and IL-10 was quantified by real-time RT-PCR using B2M and RPL27 as normalization genes. Bar graphs represent the
mean 6 SEM. Significance was tested using a two-tailed Mann-Whitney test. *P,0.05; **P,0.01. All other comparisons were not statistically
significant.
doi:10.1371/journal.pone.0109194.g004
Figure 5. 1,25(OH)2D3- or TX527-exposed human T cells from control donors and type 1 diabetes patients can suppress autologous
CD4 and CD8 T cell responses. A, B: CFSE-labeled responder cells from control (Control, n = 5–7) and type 1 diabetes (T1D, n = 7–10) donors were
stimulated for 4 days with anti-CD3/CD28 mAbs and co-cultured with autologous unsorted CD4+ (A) or sorted CD4+CD25highCD127low (B) T cell
populations (day 8) from control-, 1,25(OH)2D3- or TX527-treated cultures, as indicated. Shown are bar graphs summarizing the percentage
suppression of proliferation (see Methods section) of CD4+ (top) and CD8+ (bottom) T cells without or with Tregs at a 2:1 (in case of unsorted CD4+ T
cells, A) or 1:1 (in case of sorted CD4+CD25highCD127low T cells, B) Treg:Tresponder ratio. Significance was tested using a two-tailed Mann-Whitney
test, all not significantly different. * P,0.05. All other comparisons were not statistically significant.
doi:10.1371/journal.pone.0109194.g005
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regulatory mediators such as IL-10, TGF-b and CTLA-4 but
decreased frequencies of FOXP3+ cells, even in high inflammatory
settings. Although FOXP3 has been considered as a lineage-
specifying master regulator of Treg functions [30], several
indications that FOXP3 expression per se might not be sufficient
to stably maintain Treg suppressive function or reliably delineate
functional Tregs. For example, activated human effector T cells
can transiently express FOXP3 at a low level without acquiring
suppressive activity [38]. Also, human peripheral blood CD4+ T
cells contain a FOXP3+ T cell subpopulation that does not exhibit
suppressive activity and even produces proinflammatory cytokines
upon activation [39]. Finally, FOXP3 has a transient expression
pattern in the presence of 1,25(OH)2D3 [21], suggesting that
vitamin D-induced Tregs do not depend on FOXP3. In a recent
study, treatment of human CD4+ T cells with 1,25(OH)2D3 in
combination with IL-2 promoted the development of IL-10
producing CTLA-4+FOXP3+ T cells with suppressive capacity
[21], and we and others showed increased levels of the regulatory
cytokine IL-10 [22,40]. In vivo, IL-10 was identified as an essential
component for vitamin D-mediated inhibition of experimental
autoimmune encephalomyelitis [41] and in vitro, vitamin D-
induced IL-10-producing Tregs were able to prevent the induction
of experimental autoimmune encephalomyelitis in an IL-10
dependent way [40]. Future research will assess the role of IL10
in the suppressive function of our cultured cells, their stability
using FOXP3 TSDR demethylation analysis [42] and whether
gene polymorphisms of vitamin D genes or type 1 diabetes
susceptibility genes influence the potential of vitamin D to imprint
Treg phenotype and/or function.
In conclusion, our data show that ex vivo exposure to VDR
agonists – 1,25(OH)2D3 and the low-calcemic analog TX527 –
can increase the numbers of functional IL-10 producing
CD4+CD25highCD127low T cells with a stable phenotype and
imprint T cells with a unique homing signature and reduced
production of effector cytokines. The possibility to induce
functional Tregs from T cells isolated from type 1 diabetes
patients warrants additional validation of vitamin D-induced
Tregs for autologous adoptive immunotherapy in type 1 diabetes.
Supporting Information
Figure S1 Demographic information of the study par-
ticipants. A: Summary of the gender, age (in years as average 6
SD), number (n) of control subjects and patients with type 1
diabetes participating in the study. B: Vitamin D status measured
as 25(OH)D3 concentration in serum using 25(OH)D3 DiaSorin
RIA kit. Not all participants were included in every single
assessment described in this study.
(TIF)
Figure S2 Similar CD4/CD8 ratio and frequency of
Tregs in PBMC isolated freshly from control subject and
patients with type 1 diabetes (T1D). A: Flow cytometry data
(top) of percentage CD4+ and CD8+ T cells gated on viable CD3+
T cells in isolated PBMCs and cumulative data per donor group
(bottom) of the ratio of CD4+ to CD8+ T cells. B and C: Flow
cytometry plots (top) of CD127 versus CD25, gated on viable
CD4+ T cells (B) or CD8+ T cells (C). Gates were drawn to
determine the fractions of CD25highCD127low cells that are used in
the cumulative data graph (bottom, control: n = 41, T1D: n= 49).
Plots shown are from one representative control individual. In the
cumulative graphs, each symbol represents an individual donor.
Horizontal lines indicate the mean 6 SEM. Data are pooled from
multiple measurements at different time points. Statistical analysis
of values between controls and T1D patients was performed using
a two-tailed Mann-Whitney test. ns: not significant.
(TIF)
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